Company Pulmatrix Inc Nasdaq
Equities
US74584P1030
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Class of Inhaled Therapeutic Products
100.0
%
| 6 | 100.0 % | 7 | 100.0 % | +20.21% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 6 | 100.0 % | 7 | 100.0 % | +20.21% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Teofilo Raad
CEO | Chief Executive Officer | 54 | 02/05/17 |
Peter Ludlum
DFI | Director of Finance/CFO | 68 | 17/04/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Batycky
BRD | Director/Board Member | 56 | 31/10/19 |
Director/Board Member | 54 | 22/06/20 | |
Todd Bazemore
BRD | Director/Board Member | 53 | 30/09/20 |
Anand Varadan
BRD | Director/Board Member | 57 | 25/07/21 |
Teofilo Raad
CEO | Chief Executive Officer | 54 | 02/05/17 |
Michael Higgins
CHM | Chairman | 61 | 14/06/15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,652,285 | 3,652,260 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-1.17% | 102B | |
+2.87% | 96.09B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B |